I was beginning to worry about you, Yooo. It's been 3 weeks since you posted. So, good to know you haven't forgotten about us.
As far as the post you replied to, I was only wondering aloud if lenz may be the common denominator in the success of both trials. Obviously, it was the drug being studied in the PREACH-M trial. But as I said before, I wonder if Kevin resigned from Humanigen's Board, to dedicate his full attention to the IIT of their CAR-T, using lenz as intended by one of our patents, such as this one?
"Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab Patent number: 11673962 Abstract: Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGMCSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGMCSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided. Type: Grant Filed: October 2, 2018 Date of Patent: June 13, 2023 Assignee: HUMANIGEN, INC. Inventors: Cameron Durrant, Dale Chappell"
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.